Health ❯ Pharmaceuticals ❯ Drug Approval

FDA Regulations

AstraZeneca Compounding Pharmacies Safety Testing Rare Disease Treatments Biologics License Application MOLBREEVI BLA

Savara Investors Pressed to Seek Lead Role in Securities Suit Before Nov. 7 Deadline

Investor notices follow an FDA refusal-to-file for the MOLBREEVI application that precipitated a one-day 31.7% share drop.

GLP-1 Agonists Tied to Higher Risk of Macular Degeneration and Rare Optic Neuropathy